Carregant...

The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia

Background: Chronic Myeloid Leukemia’s (CML) treatment was optimized since the development of tyrosine kinase inhibitors (TKI) and an increased overall survival during TKI was noticed. During the TKI era, protocols for assessing response and resistance to treatment were developed. Additional chromos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Med Life
Autors principals: Crisan, AM, Coriu, D, Arion, C, Colita, A, Jardan, C
Format: Artigo
Idioma:Inglês
Publicat: Carol Davila University Press 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4656961/
https://ncbi.nlm.nih.gov/pubmed/26664479
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!